News & Updates

SGLT2i as 1L therapy for CKD: How to optimize real-world prescription?

Kidney Disease: Improving Global Outcomes (KDIGO) 2024 clinical practice guideline recommends sodium-glucose cotransporter 2 inhibitors (SGLT2i) as first-line (1L) therapy for most patients with chronic kidney disease (CKD), with or without diabetes. Despite the established cardiorenal benefits of SGLT2i, prescription remains suboptimal in real-world CKD populations. At Advances in Medicine (AIM) 2024, Professor Jennifer Green of Duke University Medical Center in Durham, North Carolina, US, discussed empagliflozin’s cardiorenal benefits in broad CKD populations and the importance of early initiation of SGLT2i therapy in delaying CKD progression, while Dr Jack Ng of the Chinese University of Hong Kong presented strategies for optimizing SGLT2i prescription in CKD.

GLP-1 RAs offer CV benefits in T2DM

Cardiovascular (CV) benefits of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) support their use in type 2 diabetes mellitus (T2DM). At a Novo Nordisk–sponsored lecture during the 6^th Annual Meeting of Endocrinology, Diabetes and Metabolism Hong Kong (EDM HK), Dr Julie Lovshin of the Division of Endocrinology and Metabolism, University of Toronto, Canada, reviewed clinical trials and real-world evidence on CV benefits provided by GLP-1 RAs, such as semaglutide, which led to guideline recommendations on their use in T2DM. Safety concerns related to GLP-1 RAs were also addressed.

Robust evidence for fenofibrate in patients with metabolic syndrome on statins

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Navigating the CPP patient journey – case-based discussion for nurses

In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.

Trimetazidine new formulation redefining angina control in daily practice

Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.

FreeStyle Libre system in T2D: Clinical evidence and case studies

At a virtual symposium fittingly held on World Diabetes Day, distinguished speakers Dr Eden Miller, Diabetologist, Diplomate of American Board of Obesity Medicine, Executive Director and Co-Founder, Diabetes Nation, Diabetes and Obesity Care, St. Charles Hospital Bend, Oregon, US, and Professor Alice Kong, Endocrinologist, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, shared clinical evidence and case studies on the use of the FreeStyle Libre continuous glucose monitoring (CGM) system in patients with type 2 diabetes (T2D). Dr Lee Lea Im Chua, Family Physician & Director, Bedok Medical Centre, Singapore, chaired this Abbott-sponsored symposium, which was well attended by healthcare professionals from the Asia Pacific region.